Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência.
Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Isturisa (osilodrostat), an approved therapy for Cushing’s disease, continues to demonstrate high and sustained responses in patients for whom pituitary gland surgery is not an option or whose disease returned after surgery, ... Read more
The Phase 3 GRACE clinical trial evaluating Corcept Therapeutics‘ relacorilant as a potential treatment for high blood pressure and poor glucose tolerance in people with endogenous Cushing’s syndrome is ... Read more
One year of treatment with under-the-skin Signifor (pasireotide) lessens tumor volume in many Cushing’s disease patients for whom surgery has failed or is not an option, a post-hoc analysis ... Read more
Blocking the EGFR signaling pathway using the breast cancer treatment lapatinib significantly reduces the amount of adrenocorticotropic hormone (ACTH) produced by pituitary tumor cells and their proliferation in mice, ... Read more
Cushing’s disease patients whose pituitary tumors carry a USP8 mutation are more likely to achieve remission after surgery than those without such mutations, a retrospective Italian study found. The ... Read more
Cushing’s syndrome patients deemed in biological remission are rarely functionally cured, continuing to report low quality of life scores, chronic depression, and the need for specific working arrangements in ... Read more
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to fluasterone (ST-002) for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatosis, and high blood sugar in Cushing’s syndrome patients, SteroTherapeutics announced. ... Read more
Strongbridge Biopharma recently received a second patent from the U.S. Patent and Trademark Office covering the use of Recorlev (levoketoconazole) for the treatment of Cushing’s syndrome. The patent (No. 9,918,984) is titled “Methods ... Read more
Pin It on Pinterest